Deaths caused by malaria this year
Grant Agreement number: RIA2018SV-2311 PfTBV RIA2018SV
The PfTBV Malaria Blocking Transmission Consortium was formed in 2019 to develop and execute on a strategy to compare, select and develop malaria vaccine candidates. Using innovative trial designs, the consortium will 1) accelerate well-established candidates into the clinic for direct comparison and evaluation 2) select the most efficacious malaria vaccine to stop transmission of Plasmodium falciparum (Pf) from humans to mosquitoes, and 3) establish assays, endpoints, and regulatory pathways for definitive efficacy assessment of a transmission blocking vaccine (TBV).
“This project (RIA2018SV-2311) is part of the EDCTP2 programme supported by the European Union”.
The burden of malaria remains intolerable, causing over 200 million clinical cases and 400,000 deaths each year, with pregnant women and children in Africa bearing the greatest risk. Malaria is caused by parasites transmitted by mosquitoes. It can cause high fever, chills, flu-like symptoms, and severe anemia and can infect your liver and blood.READ MORE
Vaccines are powerful tools that could accelerate malaria elimination efforts. Transmission-blocking vaccines (TBVs) offer a new approach by targeting developing parasites in the mosquito host (a bottleneck in the malaria parasite lifecycle) and thereby contributing to malaria elimination and potentially eradication.READ MORE
BUILDING CAPACITY FOR THE COMPARATIVE EVALUATION OF MALARIA VACCINE CANDIDATES IN SUB-SAHARAN AFRICA
- Foster a regional approach to collaborative trials among national research and regulatory bodies.